No Data
No Data
Chongqing Pharscin Pharmaceutical (002907.SZ) has launched the 'Yanpin Senhuo' series of health products.
On June 26th, Gelunhui investors asked Chongqing Pharscin Pharmaceutical (002907.SZ) on the investor interaction platform, "Does the company produce vitamins?" The company replied that it has launched the "Yanpin Senhuo" healthy living series of products, which includes a variety of vitamin-based health products such as grape seed vitamin E capsules, B vitamins, calcium vitamin D vitamin K capsules, vitamin C tablets, and collagen vitamin C vitamin E tablets.
Chongqing Pharscin Pharmaceutical (002907.SZ) has received the re-registration approval notice for the chemical raw material active pharmaceutical ingredient magnesium aluminum carbonate.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on June 25th that the company recently received the Chemistry Active Pharmaceutical Ingredient re-registration approval notice issued by the Chongqing Food and Drug Administration for Aluminum Magnesium Carbonate Chemical Raw Materials. Aluminum Magnesium Carbonate Chewable Tablets are integrated varieties of Active Pharmaceutical Ingredient, and the acquisition of the Chemistry Active Pharmaceutical Ingredient re-registration approval notice ensures the normal production of Aluminum Magnesium Carbonate and effectively guarantees the quality and supply of the active pharmaceutical ingredient. Furthermore, self-production of this chemical raw material can effectively control production costs, making this product more competitive in government procurement. The company will strictly carry out the requirements accordingly.
Chongqing Pharscin Pharmaceuticals Completes Domestic Production Registration for Hepatitis Drug
Chongqing Pharscin Pharmaceuticals (SHE:002907) completed the domestic production drug registration for its chronic viral hepatitis drug, diammonium glycyrrhizinate for injection. Changes in the drug'
Chongqing Pharscin Pharmaceutical (002907.SZ) has completed the domestic production pharmaceutical filing for injectable ammonium glycyrrhizinate.
Chongqing Pharscin Pharmaceutical (002907.SZ) announced on June 20 that the company recently learned from the website of the National Medical Products Administration that the company's product, injection-grade ammonium glycyrrhizinate, has completed the domestic production record (new production site, updated production enterprise name or address), and the record information has been made public on the website of the National Medical Products Administration.
Chongqing Pharscin Pharmaceutical (002907.SZ): The self-owned brand Quchang Aolisita capsules are currently in the market introduction period.
On June 18th, 2024, Chongqing Pharscin Pharmaceutical (002907.SZ) held an analyst conference, regarding "How is the sales situation of the company's self-owned brand Quchang Aolisita capsules?" The company replied that the self-owned brand Quchang Aolisita capsules are currently in the market introduction period, and it still takes time to ramp up the volume.
Chongqing Pharscin Pharmaceutical (002907.SZ): Currently, the sales terminals are still mainly public hospitals, and the hospital market accounts for about 70 to 80 percent.
On June 18, 2024, Chongqing Pharscin Pharmaceutical (002907.SZ) held an analyst conference to discuss "What is the proportion of the company's products inside and outside the hospital?" The company replied that its sales terminals are still mainly public hospitals, accounting for about 70-80% of the hospital market. At the same time, the company is collaborating with multiple channels to gradually increase its market share in e-commerce, new media platforms, and "three terminals".
No Data